Navigation Links
IDRI to Use NanoPass Microneedle Technology for Intradermal Vaccines and Diagnostic Skin Tests
Date:8/31/2009

SEATTLE and NES ZIONA, Israel, Aug. 31 /PRNewswire-USNewswire/ -- The Infectious Disease Research Institute (IDRI) and NanoPass Technologies Ltd. (NanoPass) today announced they have entered into an agreement whereby IDRI licenses NanoPass' proprietary MicronJet microneedle technology for the intradermal delivery of products against a number of diseases including tuberculosis, HIV, malaria, leishmaniasis and leprosy, among others. The financial details of the agreement are confidential.

NanoPass' single use, microneedles-based device can be used with any standard syringe to deliver liquid substance directly and consistently into the skin.

Intradermal vaccine delivery has been shown to induce a stronger immune response when compared to conventional administration methods such as intramuscular and subcutaneous injections. This is attributed to the relatively dense network of immune cells present in the skin, leading to a better stimulation of the body's defenses. As a result, intradermal delivery may enhance vaccine protection, facilitate development of novel vaccines for challenging diseases and allow for a reduction in the amount of antigen needed to stimulate a protective immune response.

"We are very excited to sign this license agreement with NanoPass," said Dr. Steven Reed, Founder and Head of IDRI's Research and Development. "NanoPass' MicronJet technology provides targeted delivery of the vaccine to specialized cells of the immune system. We have observed a similar immunostimulating effect with our adjuvants and we look forward to evaluating the combined potential of these technologies."

IDRI also plans to apply the MicronJet technology for the administration of diagnostic skin tests.

Because microneedles are very short, they do not reach the free nerve endings of the skin that are responsible for pain sensation, and therefore most substances can be administered with microneedles with less pain. Furthermore, the microneedles are so small that they are barely visible to the naked eye, making the MicronJet far less intimidating than a conventional needle - and perfect for children and needle-phobic patients.

Dr. Yotam Levin, CEO of NanoPass, said: "This agreement signals a new milestone for NanoPass and our MicronJet device. We are delighted to collaborate with IDRI so that this technology can be utilized in the most challenging infectious diseases that impede global health. We are excited that the MicronJet will be used to deliver innovative products targeting the needs of the poorest populations and hopefully protect many lives."

IDRI-Translating science into global health solutions

IDRI is a Seattle-based not-for-profit organization committed to applying innovative science to the research and development of products to prevent, detect and treat infectious diseases of poverty. By integrating capabilities, IDRI strives to create an efficient pathway bringing scientific innovation from the lab to the people who need it most. For more information, go to www.idri.org

About NanoPass

NanoPass (www.nanopass.com) is an Israel-based company developing an innovative delivery device for the enhancement of vaccines and other therapeutics. The Company has proven efficacy and safety in multiple applications including seasonal flu and insulin delivery. NanoPass is continuously engaged in joint clinical development with top pharmaceutical companies to demonstrate the benefits of its technology for various indications. The Company is backed by leading venture capital groups including WFD Ventures, Ofer HiTech and D-Partners.


'/>"/>
SOURCE Infectious Disease Research Institute (IDRI)
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. NanoPass Makes its MicronJet Technology Available to Increase Global Supply of Pandemic Influenza Vaccines
2. Microneedles enhance drug administration through skin
3. Quantum light beams good for fast technology
4. New Smart Technology Makes Patient Data Collection Easier, More Efficient
5. Align Technology Executive to Present at Upcoming Financial Conferences
6. Pioneer Surgical Technology Hires Vice President of New Business Development
7. Purdue researchers develop technology to detect cancer by scanning surface veins
8. Creative Technology Services Enhances its Global Competitiveness with Additional Regulatory Certifications
9. University of Wisconsin Hospitals and Clinics Complete System-Wide Conversion to Masimo SET Pulse Oximetry Technology
10. Patent Reform Legislation Threatens Americas Leadership in Medical Technology Innovation
11. Stevens Health, Technology and Society roundtable: Sept. 19
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/25/2017)... ... April 25, 2017 , ... ProRehab Physical ... be the preferred physical therapy provider for Derby City CrossFit, effective immediately. , ... CrossFit as quickly and effectively as possible, ProRehab’s sports physical therapists will work ...
(Date:4/25/2017)... ... April 25, 2017 , ... ... to compare student test score performance for the 2015-16 school year across Wisconsin’s ... voucher programs. Though it highlights important patterns in student test score performance, the ...
(Date:4/25/2017)... Switzerland (PRWEB) , ... April 25, 2017 , ... ... innovation targets, they rely on contracted partners to help with process innovation in ... of combined drug formulation experience along with state-of-the-art analytical equipment in support of ...
(Date:4/25/2017)... (PRWEB) , ... April 25, 2017 , ... Saad B. Chaudhary, MD is committed to ... of acute or chronic problems, I focus on preventative care with all my patients to ... have any questions, always feel free to contact my office and my trained staff will ...
(Date:4/25/2017)... ... , ... Vetoquinol USA® , a world-class developer of ... the EQUISTRO line, at this week’s Rolex Kentucky Three-Day Event in Lexington. Flexadin ... , The scientifically-developed Flexadin UCII supports the body’s normal repair of cartilage and ...
Breaking Medicine News(10 mins):
(Date:4/19/2017)... DALLAS , April 19, 2017 /PRNewswire/ ... that the first patients in Nashville ... in the Lower Esophageal Sphincter Stimulation for GERD (LESS ... device designed to provide long-term reflux control by restoring ... GERD affects nearly 65 million people in ...
(Date:4/19/2017)...  New research provides evidence that an old drug may ... study released today that will be presented at the ... Boston , April 22 to 28, 2017. ... disease, the oral drug levodopa has long been considered the ... the disease progresses, the effects of the medication can partially ...
(Date:4/18/2017)... Cogentix Medical, Inc. (NASDAQ: CGNT), a global medical device ... markets with innovative and proprietary products, will release financial ... after the market close on Tuesday, May 2, 2017. ... call and webcast to discuss its financial results the ... p.m. Eastern Time (3:30 p.m. Central Time). Darin ...
Breaking Medicine Technology: